NCT00062426已完成3 期
A Randomized, Prospective Study Comparing Three Regimens Of Eloxatin ™ Plus Fluoropyrimidine For Evaluation Of Safety And Tolerability In First Line Treatment Of Patients With Advanced Colorectal Cancer (Tree Study)
Prologue Research International102 个研究点 分布在 1 个国家开始时间: 2003年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 102
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different combinations may kill more tumor cells. Monoclonal antibodies, such as bevacizumab (Avastin™), can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known which regimen works better in treating advanced colorectal cancer.
PURPOSE: This randomized phase III trial is to see if oxaliplatin and bevacizumab work better when combined with either fluorouracil and leucovorin or capecitabine in treating patients who have metastatic or recurrent colorectal cancer.
详细描述
OBJECTIVES:
- Compare the incidence of grade 3 and 4 toxic effects occurring within the first 12 weeks of treatment with 2 different schedules of oxaliplatin, bevacizumab (Avastin™), leucovorin calcium, and fluorouracil or with oxaliplatin, Avastin™, and capecitabine in patients with advanced colorectal cancer.
- Compare the overall response rate, progression-free survival, and time to treatment failure in patients treated with these regimens.
- Compare the composite toxicity of these regimens in these patients.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive bevacizumab (Avastin™) IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil (5-FU) IV over 46 hours beginning on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive Avastin™ IV over 30-90 minutes and oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium IV over 10 minutes and 5-FU IV over 3 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- Arm III: Patients receive Avastin™ IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 month, every 3 months for at least 2 years, and then every 6 months thereafter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed adenocarcinoma of the colon or rectum
- •Metastatic or recurrent disease not amenable to potentially curative treatment
- •At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- •Histological or cytological confirmation is required for a solitary target lesion
- •No CNS metastases
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Absolute neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Bilirubin no greater than 2 times upper limit of normal (ULN)
- •SGPT and SGOT no greater than 3 times ULN
- •Creatinine no greater than 1.5 times ULN
- •Creatinine clearance at least 30 mL/min
- •Cardiovascular
- •No myocardial infarction within the past 6 months
- •No clinical evidence of congestive heart failure
- •No unstable coronary artery disease
- •No interstitial pneumonia
- •No extensive symptomatic fibrosis of the lungs
- •Gastrointestinal
- •Able to tolerate oral medication
- •No lack of physical integrity of the upper gastrointestinal tract
- •No malabsorption syndrome
- •No swallowing difficulties
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 6 months after study participation
- •No other concurrent serious illness
- •No uncontrolled infection
- •No other concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix or any other cancer for which the patient has been off all therapy and in remission for at least 5 years
- •No peripheral neuropathy
- •No hypersensitivity to any of the study drugs or their ingredients
- •No known dihydropyrimidine dehydrogenase deficiency
- •No other medical or psychiatric disorder that would preclude giving informed consent or complying with study
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •No concurrent prophylactic hematopoietic growth factor therapy
- •No prior bevacizumab (Avastin™)
- •Chemotherapy
- •At least 6 months since prior adjuvant fluorouracil, leucovorin calcium, and irinotecan
- •No prior oxaliplatin
- •No prior chemotherapy for metastatic or recurrent disease
- •No other concurrent chemotherapy
- •Endocrine therapy
- •Not specified
- 另有 10 项未显示
排除标准
- 未提供
研究者
研究点 (102)
Loading locations...
相似试验
进行中（未招募）
3 期
Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon CancerColorectal CancerNCT00958737GERCOR - Multidisciplinary Oncology Cooperative Group2,000
终止
3 期
Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal CancerMetastatic CancerColorectal CancerNCT00268463NSABP Foundation Inc22
已完成
3 期
Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryPancreatic CancerNCT00303758Federation Francophone de Cancerologie Digestive202
Unknown
不适用
Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the EyeRetinoblastomaNCT00360750Children's Cancer and Leukaemia Group
终止
3 期
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal CancerAdenocarcinoma of the RectumStage II Rectal CancerStage III Rectal CancerNCT00303628ECOG-ACRIN Cancer Research Group355